Myelofibrosis (MF) Video Channel
Explore the latest insights and summaries from experts in Myelofibrosis (MF).
Therapeutic Agents
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volume Reduction in Patients with PV
FEATURING
Claire Harrison
- 461 views
- July 1, 2024
- 1
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
FEATURING
Claire Harrison
- 649 views
- July 1, 2024
Vanderbilt University Medical Center (VUMC)
Management of MF After Ruxolitinib Failure
FEATURING
Ashwin Kishtagari
- 204 views
- July 18, 2024
- 2
MyCancerHaven
Experts Discuss Their Current Approach to Treating MF
FEATURING
Ravi Vij,
Abdulraheem Yacoub
- 129 views
- August 30, 2024
Incyte
Importance of Early Management of Patients with Myelofibrosis (MF)
FEATURING
Prithviraj Bose,
Raajit Rampal
- 270 views
- October 10, 2024
- 2
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current and Future Treatment Landscape of Myelofibrosis
FEATURING
Rami Komrokji
- 177 views
- October 8, 2024
- 1
Yale Cancer Center
Myeloid Malignancies: Hot Topics in 2024
FEATURING
Nikolai Podoltsev
- 301 views
- October 21, 2024
Cleveland Clinic Taussig Cancer Institute
Updates in MPNs From ASH 2023
FEATURING
Rebecca B. Klisovic
- 12 views
- October 22, 2024
Alexander Coltoff
Survival as a Primary Goal in MF: Evaluating 5-Yr Data From COMFORT-1
- 89 views
- November 5, 2024
Indy Hematology Review
2024 Updates on Myelofibrosis and Systemic Mastocytosis
FEATURING
Raajit Rampal
- 342 views
- April 16, 2024
- 1
University of Colorado Division of Hematology
2024 Updates in MF
FEATURING
Brandon McMahon
- 78 views
- April 19, 2024
- 1
Prithviraj Bose
MANIFEST-2 Study: Pelabresib With Ruxolitinib for JAKi-Naïve Patients With Myelofibrosis
- 221 views
- April 22, 2024
- 1
Mary Frances McMullin
Quality of Life in Myelofibrosis Patients Treated With Momelotinib
- 213 views
- April 26, 2024
Memorial Sloan Kettering Cancer Center
Key Updates in AML, MDS, & MF From ASH
FEATURING
Aaron Goldberg
- 313 views
- May 2, 2024
- 4
Moffitt Cancer Center
Current Treatment Landscape of JAK Inhibitors in MF
FEATURING
Andrew Kuykendall
- 239 views
- May 13, 2024
Yale Cancer Center
Emerging Therapies in MF & PV: Insights From Recent Clinical Trials
FEATURING
Jan Bewersdorf
- 167 views
- May 14, 2024
- 1
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: MPN
FEATURING
John Mascarenhas
- 259 views
- March 22, 2024
Icahn School of Medicine at Mount Sinai
Stem Cell Pathways, Aging, and Cancer Evolution in MPN
FEATURING
Catriona Jamieson
- 20 views
- July 2, 2024
Icahn School of Medicine at Mount Sinai
Strategies to Overcome Immune Dysregulation in MPNs
FEATURING
Cansu Cimen Bozkus
- 30 views
- July 2, 2024
16th International Congress on Myeloproliferative Neoplasms
Clinical and Therapeutic Aspects of Chronic Inflammation in the MPNs
FEATURING
Hans Hasselbalch
- 48 views
- November 26, 2024
- 1
16th International Congress on Myeloproliferative Neoplasms
Selection of JAK1/2 Inhibitors for Primary Myelofibrosis
FEATURING
Aaron Gerds
- 89 views
- December 3, 2024
16th International Congress on Myeloproliferative Neoplasms
Novel Agents for MPNs in 2024
FEATURING
Naveen Pemmaraju
- 121 views
- December 3, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: MPN Highlights and Clinical Implications
FEATURING
Douglas Tremblay
- 289 views
- December 18, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ph3 BOREAS Study - Navtemadlin vs. Best Available Therapy in JAK Inhibitor R/R MF
FEATURING
John Mascarenhas
- 34 views
- December 27, 2024
Integrity CE
Collaborative Care in MF - Community and Academic Physicians Discuss Managing a Complicated Case
FEATURING
Luke Fletcher,
Aaron Gerds
- 124 views
- January 24, 2024
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implications"
FEATURING
Douglas Tremblay
- 407 views
- January 26, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Advances and Unmet Needs in MPN Treatment
FEATURING
Daniela Cilloni
- 81 views
- February 21, 2024
Winship Cancer Institute - Emory University
COMFORT-1 Trial Long-Term Follow-Up: Impact of Ruxolitinib on OS for Myelofibrosis Patients
FEATURING
Anthony Hunter
- 44 views
- December 31, 2024
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Management of Myelofibrosis in Special Patient Populations
FEATURING
John Mascarenhas
- 148 views
- October 9, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Novel Non-JAK Inhibitor Therapies for Myelofibrosis
FEATURING
John Mascarenhas
- 228 views
- October 10, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Choosing and Properly Using a JAK Inhibitor in Myelofibrosis
FEATURING
Anthony Hunter
- 91 views
- October 16, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Future Directions in the Management of Myelofibrosis
FEATURING
Andrew Kuykendall
- 90 views
- October 18, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Clinical Decision-Making for Patients With Myelofibrosis
FEATURING
Prithviraj Bose
- 74 views
- October 18, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Addressing Anemia in Myelofibrosis
FEATURING
Stephen Oh
- 226 views
- October 18, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Next Questions: Myeloproliferative Neoplasms
FEATURING
John Mascarenhas
- 64 views
- October 19, 2023
- 1
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "PIM1 Kinase Inhibitor TP-3654 for R/R Myelofibrosis"
FEATURING
Lindsay Rein
- 37 views
- December 19, 2023
Insights from 2023 ASH Annual Meeting
Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis
FEATURING
Douglas Tremblay
- 433 views
- December 13, 2023
- 1
UChicago Medicine
Current Management of Accelerated/Blast-Phase MPNs
FEATURING
Anand Patel
- 76 views
- October 25, 2024
- 1